TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19672055
Drug: Structured written
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured written and oral information about asthma and asthma medication, and asthma diary
Study: 18576945
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine (1.9, 3.8, 7.5, or 15 microg of hemagglutinin)
Study: 18576945
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine (higher doses)
Study: 18576945
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (7.5 microg of hemagglutinin)
Study: 11989073
Drug: Intensive follow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive follow up (40 patients), controlled every 2 months with physical examination and lipid profile, diet and exercise enhancement, and statin dose adjustment.
Study: 7794578
Drug: Diltiazem OD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem OD ER 240 mg
Study: 7794578
Drug: Diltiazem OD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem OD ER 540 mg
Study: 7794578
Drug: Diltiazem OD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem OD ER 360 mg
Study: 7794578
Drug: Diltiazem OD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem OD ER 240 mg and above
Study: 7000264
Drug: sulphinpyrazone 200
Normalized name: Sulphinpyrazone
DrugBank: Sulfinpyrazone (DB01138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulphinpyrazone 200 mg four times daily
Study: 30113933
Drug: Suprachoroidal injection
Normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprachoroidal injection of CLS-TA 4.0 mg
Study: 30113933
Drug: Suprachoroidal injection
Normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprachoroidal injection of CLS-TA 0.8 mg
Study: 27862339
Drug: Cooling compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling compound (CC) lotion applied twice daily for 4 weeks
Study: 27862339
Drug: Cooling compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling compound (CC) lotion
Study: 22561365
Drug: Adenovirus serotype
Normalized name: Human Adenovirus Serotype 4 Strain Cl-68578
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus serotype 5 (Ad5)‐vectored HIV vaccine
Study: 21203519
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo pills (inert substance, like sugar pills)
Study: 21203519
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo pills
Study: 16320346
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/day) plus elemental calcium (1,200 mg/day)
Study: 12856761
Drug: Object of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Object of My Affection (treatment group)
Study: 7989461
Drug: Pamidronate (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (150 mg/day)
Study: 3053570
Drug: Spiramycin 2
Normalized name: spiramycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiramycin 2 g orally daily
Study: 3053570
Drug: Erythromycin 2
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 2 g orally daily
Study: 27622692
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg (two injections at baseline and after 6 months, n=10)
Study: 27622692
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg (n=10)
Study: 27622692
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n=14)
Study: 23899063
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with doxorubicin and paclitaxel
Study: 20070351
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg once daily (N = 528)
Study: 20070351
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg twice daily (N = 522)
Study: 18760583
Drug: TIO 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO 18 microg once-daily (8 am) + FOR 12 microg (8 pm)
Study: 18760583
Drug: FOR 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOR 12 microg twice-daily (8 am and 8 pm) + TIO 18 microg (8 pm)
Study: 18760583
Drug: Single-drug treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug treatments
Study: 18760583
Drug: Tr4 (TIO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tr4 (TIO 18 microg (8 am) + FOR 12 microg twice-daily (8 am and 8 pm))
Study: 18760583
Drug: Tr5 (FOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tr5 (FOR 12 microg twice-daily (8 am and 8 pm) + TIO 18 microg (8 pm))
Study: 12673696
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy regimens incorporating gemcitabine and paclitaxel with a platinum complex, with or without ifosfamide or doxorubicin
Study: 12673696
Drug: Standard single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard single agents (methotrexate, doxorubicin, mitomycin, ifosfamide, vinblastine, cisplatin)
Study: 6364688
Drug: i.m. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. injection of 15‐methyl PGF2 alpha, 0.25 mg every second hour
Study: 6364688
Drug: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2 methyl sulfonyl‐amide, 0.5 mg every fourth hour
Study: 27191923
Drug: Remifentanil (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (target concentration: young 3 ng/ml; old 2 ng/ml)
Study: 27191923
Drug: Morphine (dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (dose: young 0.1 mg/kg; old 0.07 mg/kg)
Study: 22200383
Drug: Active US
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active US therapy (20% duty cycle, 1MHz, average temporal intensity: 0.2W/cm(2), therapeutic dose: 112.5J/cm(2))
Study: 22200383
Drug: Sham US
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham US therapy (no sound-head crystal)
Study: 21047602
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 1 ml Orthovisc(®) hyaluronic acid injections
Study: 21047602
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml single dose Orthovisc(®) hyaluronic acid injections
Study: 21047602
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml single dose Orthovisc(®) hyaluronic acid injections
Study: 21047602
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml single dose Orthovisc(®) hyaluronic acid injections
Study: 17685257
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with irinotecan + 5-FU + leucovorin
Study: 11856774
Drug: SYNSORB Pk
Normalized name: Synsorb Pk
DrugBank: TAK-751S (DB06432)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNSORB Pk treatment (n = 19)
Study: 7702016
Drug: Intravenous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of pure fat or carbohydrate (2092 kJ)
Study: 7702016
Drug: Intragastric infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric infusions of fat or carbohydrate (2092 kJ)
Study: 7702016
Drug: Slow intragastric
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow intragastric infusions of fat
Study: 7702016
Drug: Slow intragastric
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow intragastric infusions of carbohydrate
Study: 30079951
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (200 mg of ferrous fumarate weekly for 3 months)
Study: 26151734
Drug: Sesamin 200
Normalized name: SESAMIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesamin 200 mg/day
Study: 23640622
Drug: Standard dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysate sodium concentration (138 mmol/L)
Study: 20884297
Drug: HBVaxPro monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBVaxPro monovalent hepatitis B vaccine
Study: 20884297
Drug: Engerix B
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix B monovalent hepatitis B vaccine
Study: 15087038
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Reduced Glutathione (GSH)
Study: 20858149
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg three times a day)
Study: 7759671
Drug: Deep pressure/touch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep pressure/touch therapies
Study: 7759671
Drug: Stress‐challenge treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress‐challenge treatments
Study: 7759671
Drug: Confrontational scare
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confrontational scare treatments
Study: 2496000
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg b.i.d)
Study: 31173130
Drug: Deep learning
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep learning model (HeadXNet) augmentation
Study: 26666596
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and exercise treatment for 3-6 months to reduce body weight by >5%
Study: 23682110
Drug: Macitentan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan (10 mg once daily)
Study: 21802649
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg (high dose)
Study: 21802649
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg (low dose)
Study: 21802649
Drug: 0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/kg (placebo)
Study: 21802649
Drug: Alcohol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (all doses)
Study: 16960474
Drug: Intrathecal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal triamcinolone acetonide (6 injections every third day)
Study: 9161943
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral vitamin K1 supplementation per week for 4 weeks
Study: 7910126
Drug: Khat (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Khat (0.8 mg/kg body weight)
Study: 31813317
Drug: Videoconference administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Videoconference administration of MoCA
Study: 31813317
Drug: Face-to-face administration
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face administration of MoCA
Study: 29871369
Drug: Lower one-third
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower one-third joint technique (group L)
Study: 27271500
Drug: SpeechEasy® device
Approvals — FDA: no, EMA: no, PMDA: no
Description: SpeechEasy® device used daily for 6 months
Study: 22487170
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical education (5 × 45 min/week) and adapted motor training if needed
Study: 20007734
Drug: Nabilone (0.5-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (0.5-1.0 mg before bedtime)
Study: 20007734
Drug: Amitriptyline (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10-20 mg before bedtime)
Study: 11920267
Drug: Oral fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fludarabine phosphate on a full stomach
Study: 11920267
Drug: Oral fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fludarabine phosphate on a fasted stomach
Study: 9439551
Drug: Leucine infusion
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine infusion
Study: 3661609
Drug: Sucralfate (Carafate)
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate (Carafate) 1 g
Study: 3661609
Drug: Cimetidine (Tagamet)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (Tagamet) 300 mg
Study: 3661609
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 g
Study: 11466599
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (n=46)
Study: 11466599
Drug: Psychodynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic treatment (n=52)
Study: 9236433
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral carvedilol treatment
Study: 31693806
Drug: Intravenous amoxicillin‐clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amoxicillin‐clavulanate (1 g and 200 mg, respectively) administered three times a day for 2 days, starting less than 6 hours after cardiac arrest.
Study: 31693806
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times a day for 2 days, starting less than 6 hours after cardiac arrest.
Study: 28577545
Drug: Intervention (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (two dietary consultations and access to twice‐weekly exercise groups)
Study: 25082656
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg/day for three months
Study: 21807696
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (400 mg daily from 18 to 22 weeks' gestation through parturition)
Study: 17014635
Drug: Face washing
Normalized name: Phisoderm Clear Confidence Daily Gel Face Wash
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face washing twice a day with a standard mild cleanser
Study: 17014635
Drug: Face washing
Normalized name: Phisoderm Clear Confidence Daily Gel Face Wash
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face washing twice a day (control group)
Study: 10664923
Drug: IS‐5‐MN 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IS‐5‐MN 20 mg immediate release
Study: 10664923
Drug: IS‐5‐MN 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: IS‐5‐MN 50 mg sustained release
Study: 9297869
Drug: i.v. omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. omeprazole, 40 mg bolus followed by 80 mg/day by continuous infusion for 3 days
Study: 9297869
Drug: i.v. ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ranitidine 50 mg i.v. bolus followed by 400 mg/day i.v., continuous infusion for 3 days
Study: 8345983
Drug: IVGG (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVGG (400 mg/kg/day for 4 consecutive days)
Study: 30152049
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) of DEC and albendazole
Study: 26801098
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (150 min weekly of combined aerobic and resistance training)
Study: 22304620
Drug: Mentholated cream
Normalized name: camphor / menthol Topical Ointment [Mentholatum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentholated cream plus oxygenated glycerol triesters (MC + OGTs)
Study: 22304620
Drug: Mentholated cream
Normalized name: camphor / menthol Topical Ointment [Mentholatum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentholated cream (MC)
Study: 18514323
Drug: Schizophrenia patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schizophrenia patients with shorter duration of antipsychotic drug exposure
Study: 8740043
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg phenelzine every other day, then 15 mg daily for 6 weeks
Study: 1846872
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (CEE) + 5 mg medroxyprogesterone acetate (days 15-25)
Study: 1846872
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg CEE + placebo (days 15-25)
Study: 1846872
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg CEE (days 1-25)
Study: 1846872
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg CEE (days 1-25)
Study: 6760968
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg oral dose)
Study: 31232940
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg twice daily 1 day before and 3 days after the operation)
Study: 31232940
Drug: Control (hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (hydration from 12 hours before to 12 hours after contrast administration)
Study: 25916131
Drug: Intravenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous laser therapy (10-day course) using 'matrix-vlok' apparatus, wavelength 0.405 microns, radiation power 1-1.5 mW, continuous mode
Study: 11471442
Drug: Normovolemic hemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normovolemic hemodilution (NVH) with blood withdrawal of 6-8 ml.kg-1 and intravenous colloid substitution
Study: 7865434
Drug: Paclitaxel 250
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 250 mg/m2 i.v. over 24 hours every 3 weeks
Study: 7865434
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 to 250 mg/m2 i.v. over 24 hours every 3 weeks
Study: 7865434
Drug: Cisplatin/etoposide chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/etoposide chemotherapy (standard)
Study: 7865434
Drug: Paclitaxel 135
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg/m2 i.v. over 24 hours plus cisplatin 75 mg/m2 i.v.
Study: 7865434
Drug: Paclitaxel 250
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 250 mg/m2 i.v. over 24 hours plus cisplatin 75 mg/m2 i.v. plus recombinant human granulocyte colony-stimulating factor
Study: 2494240
Drug: Transdermal nitroglycerin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin, 10 or 20 cm2 (5 or 10 mg/24 h) (Group A)
Study: 2494240
Drug: Transdermal nitroglycerin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin, 30 or 40 cm2 (15 or 20 mg/24 h) (Group B)
Study: 31537025
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg/day)
Study: 31537025
Drug: Deflazacort (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort (30 mg/day)
Study: 31537025
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Tamsulosin and Deflazacort)
Study: 31537025
Drug: Paracetamol on
Normalized name: Paracetamol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol on demand (Control group)
Study: 25062611
Drug: Bacillus subtilis
Normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus subtilis R0179 at 0.1×10^9 cfu/capsule/day
Study: 25062611
Drug: Bacillus subtilis
Normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus subtilis R0179 at 1.0×10^9 cfu/capsule/day
Study: 25062611
Drug: Bacillus subtilis
Normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus subtilis R0179 at 10×10^9 cfu/capsule/day
Study: 21282540
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 100 mg/d
Study: 21282540
Drug: Warfarin (WAR)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (WAR) 1.25 mg/d
Study: 21282540
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - Enoxaparin 40 mg/d
Study: 18164303
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg subcutaneous depot every 4 weeks for 3 doses)
Study: 18164303
Drug: Leuprolide (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (3.75 mg subcutaneous depot every 4 weeks for 3 doses)
Study: 16474028
Drug: Rifapentine 900
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 900 mg/isoniazid 900 mg once weekly for 12 weeks
Study: 16474028
Drug: Rifampin 450-600
Normalized name: rifampin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 450-600 mg/pyrazinamide 750-1,500 mg daily for 8 weeks
Study: 8864797
Drug: Fenofibrate 250
Normalized name: fenofibrate 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 250 mg retard capsules
Study: 8864797
Drug: Lipanthyl 250
Normalized name: Lipanthyl
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lipanthyl 250 mg retard capsules
Study: 1617931
Drug: amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin‐clavulanic acid (500 mg/125 mg t.i.d.)
Study: 6366550
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with fluorouracil and semustine
Study: 6366550
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with methanol extraction residue of BCG
Study: 6366550
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with fluorouracil, semustine, and immunotherapy
Study: 6366550
Drug: Close follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Close follow-up without adjuvant treatment